Independence Bank of Kentucky Has $565,000 Stock Position in Boston Scientific Corporation $BSX

Independence Bank of Kentucky grew its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 1,602.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,790 shares of the medical equipment provider’s stock after purchasing an additional 5,450 shares during the quarter. Independence Bank of Kentucky’s holdings in Boston Scientific were worth $565,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC raised its holdings in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares in the last quarter. Martingale Asset Management L P boosted its stake in shares of Boston Scientific by 304.0% during the 1st quarter. Martingale Asset Management L P now owns 20,247 shares of the medical equipment provider’s stock worth $2,043,000 after acquiring an additional 15,235 shares in the last quarter. Compound Planning Inc. increased its holdings in shares of Boston Scientific by 9.0% during the 1st quarter. Compound Planning Inc. now owns 10,495 shares of the medical equipment provider’s stock valued at $1,059,000 after acquiring an additional 864 shares during the last quarter. 1832 Asset Management L.P. raised its stake in shares of Boston Scientific by 11.1% in the 1st quarter. 1832 Asset Management L.P. now owns 848,147 shares of the medical equipment provider’s stock valued at $85,561,000 after acquiring an additional 84,585 shares in the last quarter. Finally, Groupe la Francaise raised its stake in shares of Boston Scientific by 13.1% in the 1st quarter. Groupe la Francaise now owns 335,082 shares of the medical equipment provider’s stock valued at $33,591,000 after acquiring an additional 38,701 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 143,095 shares of company stock worth $14,228,950 over the last three months. Company insiders own 0.50% of the company’s stock.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: RBC Capital continues to rate BSX as an “outperform,” reinforcing buy-side support from a major bank and likely helping demand for shares. RBC Capital maintains Boston Scientific (BSX) outperform recommendation
• Positive Sentiment: Royal Bank of Canada analyst commentary suggests upside ahead for BSX, adding another institutional voice expecting price appreciation. This supports the bullish narrative among analysts. Boston Scientific (NYSE:BSX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
• Positive Sentiment: Truist reaffirmed a “buy” rating on BSX, signaling continued analyst confidence even as the firm updated its outlook—this helps underwrite medium-term investor sentiment. Truist Securities maintains Boston Scientific (BSX) buy recommendation
• Positive Sentiment: Zacks highlights BSX’s global expansion push — R&D, AI-driven manufacturing and a focused Emerging Markets effort targeting $1B+ revenue in China for 2025 — a strategic growth catalyst that supports longer-term upside. Boston Scientific’s Global Expansion: What’s Behind the Growth?
• Neutral Sentiment: Options flow is active around BSX; Benzinga’s options-focused piece notes positioning that can amplify intraday moves but doesn’t definitively indicate directional conviction from fundamental investors. Watch open interest and strike concentration for short-term signals. Decoding Boston Scientific’s Options Activity: What’s the Big Picture?
• Neutral Sentiment: Informational pieces recap BSX’s multi-year performance; useful for context but unlikely to move the stock today. These highlight solid historical returns that underpin investor confidence. Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 5 Years
• Neutral Sentiment: Short-term market commentary notes BSX outperformed earlier sessions; useful for momentum traders but not a standalone fundamental driver. Boston Scientific (BSX) Advances While Market Declines
• Negative Sentiment: Truist cut its price target from $130 to $120 — a downward revision that may cap near-term upside and pressures sentiment despite the maintained “buy” rating. That target trim likely explains some of the selling pressure today. BSX price target lowered by Truist

Boston Scientific Trading Down 0.5%

Shares of BSX stock opened at $95.61 on Friday. The firm has a fifty day moving average of $98.64 and a 200-day moving average of $101.26. The stock has a market cap of $141.74 billion, a price-to-earnings ratio of 51.13, a P/E/G ratio of 1.93 and a beta of 0.67. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the previous year, the firm posted $0.63 earnings per share. The firm’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on BSX shares. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. Needham & Company LLC restated a “buy” rating and issued a $121.00 price objective on shares of Boston Scientific in a research note on Friday, October 17th. Morgan Stanley raised their target price on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Leerink Partners lifted their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Finally, Robert W. Baird boosted their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Boston Scientific currently has a consensus rating of “Buy” and an average price target of $124.85.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.